Kamada Ltd.
TASE:KMDA Rapporto sulle azioni
Kamada Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Kamada ha un patrimonio netto totale di $251.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $351.0M e $99.9M. L'EBIT di Kamada è $16.8M rendendo il suo rapporto di copertura degli interessi -8.5. Ha liquidità e investimenti a breve termine pari a $56.5M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi -8.5x Contanti US$56.55m Patrimonio netto US$251.15m Totale passività US$99.89m Totale attività US$351.04m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06 Kamada Ltd., Annual General Meeting, Dec 11, 2024 Oct 22
Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023) Aug 15
Kamada Ltd. Provides Earnings Guidance for the Year 2024 Aug 15
Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07
First quarter 2024 earnings released May 09 Kamada Ltd. Raises Earnings Guidance for the Year 2024 May 09
Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024 May 03
Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality Mar 14
Full year 2023 earnings released: EPS: US$0.17 (vs US$0.052 loss in FY 2022) Mar 07
Kamada Ltd. Provides Revenue Guidance for the Year 2024 Mar 06
Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024 Feb 29
Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29% Dec 30
Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year Dec 22
Investor sentiment improves as stock rises 19% Dec 06
Third quarter 2023 earnings released: EPS: US$0.07 (vs US$0.011 in 3Q 2022) Nov 14
Kamada Ltd., Annual General Meeting, Dec 28, 2023 Nov 14
Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023 Nov 09
Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data Oct 17
New minor risk - Shareholder dilution Sep 09
Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023 Aug 17
Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.09 loss in 2Q 2022) Aug 17
Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023 Aug 10
First quarter 2023 earnings released: US$0.04 loss per share (vs US$0.04 loss in 1Q 2022) May 26 Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.
Kamada Ltd. to Report Q1, 2023 Results on May 24, 2023 May 19
Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland May 17
Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in Israel May 04
Full year 2022 earnings released: US$0.05 loss per share (vs US$0.05 loss in FY 2021) Mar 16
Is Kamada (TLV:KMDA) Using Too Much Debt? Jan 26
Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in Israel Jan 05
Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors Dec 23
Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023 Dec 20
We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed Dec 16
Third quarter 2022 earnings released: EPS: US$0.01 (vs US$0.02 loss in 3Q 2021) Nov 23
Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022 Nov 23
Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022 Nov 17
High number of new directors Nov 16
Kamada Ltd., Annual General Meeting, Dec 22, 2022 Nov 09
Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical Trial Nov 08
Second quarter 2022 earnings released: US$0.09 loss per share (vs US$0.02 profit in 2Q 2021) Aug 18
Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022 Aug 18
Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022 Aug 11
Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022 Jun 02
First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.06 profit in 1Q 2021) May 19
Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022 May 19 Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022
Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022 May 12
High number of new directors Apr 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 15
Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022 Mar 04
Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics Nov 24
Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Nov 23
Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index Aug 14
Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020) Aug 13
Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children Jun 03
First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020) May 13
Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. Mar 05
New 90-day low: ₪20.12 Mar 02
Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38% Mar 01
Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019) Feb 11
Revenue misses expectations Feb 11
Investor sentiment improved over the past week Feb 10
New 90-day high: ₪24.74 Feb 08
Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders? Feb 08
Kamada Ltd. to Report Q4, 2020 Results on Feb 10, 2021 Feb 04
Kamada Ltd. (TASE:KMDA) entered into an agreement to acquire Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. for $1.6 million. Feb 02
Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? Jan 21
Kamada Ltd. Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel Jan 14
Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate Jan 03
How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year? Dec 15
New 90-day low: ₪21.50 Dec 08
Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential? Nov 29
Revenue beats expectations Nov 13
Third quarter 2020 earnings released: EPS US$0.15 Nov 13
Kamada Ltd. Appoints Yifat Philip, Esq. as Vice President Legal, General Counsel and Corporate Secretary Nov 12
Kamada Ltd. to Report Q3, 2020 Results on Nov 11, 2020 Nov 05
Market pulls back on stock over the past week Oct 29
New 90-day low: ₪25.40 Oct 27
Kamada Ltd. Signs Agreement with the Israeli Ministry of Health to Supply its Anti-SARS-CoV-2 Plasma-Derived Hyperimmune Immunoglobulin Product for the Treatment of Coronavirus Patients in Israel Oct 20
New 90-day low: ₪27.56 Oct 04
New 90-day high - ₪33.35 Aug 17
First half earnings released Aug 13
Kamada Ltd. announced that it has received $25.000002 million in funding Aug 13
Kamada Ltd. to Report Q2, 2020 Results on Aug 12, 2020 Aug 06
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $166.4M ) di KMDA superano le sue passività a breve termine ( $40.9M ).
Passività a lungo termine: Le attività a breve termine di KMDA ( $166.4M ) superano le sue passività a lungo termine ( $59.0M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: KMDA è esente da debiti.
Riduzione del debito: KMDA non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.8%.
Copertura del debito: KMDA non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo .
Copertura degli interessi: KMDA non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
